CS
CRDL

Credit Suisse’s Cardiol Therapeutics CRDL Stock Holding History

Credit Suisse’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$194K Hold
80,000
– – ﹤0.01% 2902
2023
Q4 		$88K Buy
80,000
+30,000
+60% +$25.5K ﹤0.01% 3031
2023
Q3 		$62K Buy
+50,000
New +$47.8K ﹤0.01% 3112

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
MOS
MGO One Seven Beachwood, Ohio $4.98B AUM 22.72% 1-Year Est. Return
LSA
Lion Street Advisors Austin, Texas $289M AUM 3.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's CRDL Position: Q1 2024 in Review

Credit Suisse held its Cardiol Therapeutics (CRDL) position steady in Q1 2024 at 80,000 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #2902.

Credit Suisse first reported a position in CRDL in Q3 2023 and has held it in 3 quarters since. 35 funds tracked by Wall St. Rank hold CRDL as of Q1 2024.

  • Credit Suisse held 80,000 shares of Cardiol Therapeutics worth $194K as of Q1 2024.
  • Credit Suisse left its Cardiol Therapeutics share count unchanged in Q1 2024.
  • Cardiol Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2902 holding.
  • Credit Suisse first reported a position in Cardiol Therapeutics in Q3 2023 and has held it in 3 quarters since.
  • 35 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.